We utilized the B16-SIY melanoma model, CD11c-DTR-GFP bone marrow chimeras and CD11c-DTR-GFP/Batf3 KO mixed bone marrow chimeras to study the role Batf3-DCs play during anti-PD-L1 immunotherapy. This evidence concerns the gene BATF3 and melanoma.